Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NHS England has announced a programme to provide NHS staff with evidence-based digital programmes to protect their mental health during the COVID-19 response. The apps are designed to help maintain healthy sleep, and reduce anxiety.

Sleepio is an automated digital self-help app based on cognitive behavioural therapy for insomnia. It was built by Colin Espie, Professor of Sleep Medicine at the Nuffield Department of Clinical Neurosciences and Co-Founder of digital therapeutics company Big Health. Subsequent research by Espie and his team has demonstrated the efficacy and safety of Sleepio, and provided a platform for recognition of the value of digital therapeutics more widely in the NHS and other workplaces internationally.

Fifteen NHS trusts and six GP practices have already rolled out access to Sleepio and Daylight, an app designed to help with worry and anxiety. These apps have now been made freely available to all NHS employees across the country in partnership with NHS England.

Professor Colin Espie has praised NHS England’s quick response in protecting the mental health of NHS staff as well as their physical health during the pandemic. He said: ‘I’m honoured that Big Health is able to support our colleagues in the NHS to help safeguard their mental health during these most challenging of times. NHS staff are working under enormous pressure while also experiencing significant changes to their lives at home as a result of COVID-19.’

To learn how to gain access to Daylight and Sleepio for your staff, please email ceo@bighealth.com

Similar stories

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Appointment of the new Margaret Ogilvie Professor of Ophthamology

We are delighted to announce that Professor Denize Atan has joined the department as Margaret Ogilvie Professor of Ophthamology and a Consultant in Neuro-ophthalmology at the Oxford Eye Hospital.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.